Cytisine, the world’s oldest smoking cessation aid

@article{Prochaska2013CytisineTW,
  title={Cytisine, the world’s oldest smoking cessation aid},
  author={Judith J. Prochaska and Smita Das and Neal L. Benowitz},
  journal={BMJ : British Medical Journal},
  year={2013},
  volume={347}
}
Growing evidence for its use as an affordable treatment globally 
The case for licensing cytosine now for smoking cessation is overwhelming
TLDR
An excellent overview of cytisine in smoking cessation fails to highlight the compelling cost-benefit evidence on why this effective, safe, and inexpensive drug should be licensed immediately worldwide. Expand
Cytisine--a tobacco treatment hiding in plain sight.
  • N. Rigotti
  • Medicine
  • The New England journal of medicine
  • 2014
A randomized, controlled trial published in this issue of the Journal brings renewed attention to cytisine, a potentially useful pharmacotherapy for smoking cessation that has been hiding in plainExpand
Pharmacological therapies in smoking cessation: an evidence-based update
TLDR
Recent updates to the literature regarding nicotine replacement, bupropion, and varenicline are reviewed; re-emerging therapies such as cytisine are reviewed, as well as the novel concept of vaccination. Expand
Cytisine versus nicotine for smoking cessation.
TLDR
Although cytisine is perceived as a novelty in the West, it has been used in daily medical practice in Poland for more than 50 years and is currently undergoing a renaissance in Poland. Expand
The effectiveness of Cytisine versus Nicotine Replacement Treatment for smoking cessation in the Russian Federation.
TLDR
Findings appear to support previous trial evidence that cytisine is superior to NRT in helping smokers quit, and are found to be more effective than NRT for 90-day abstinence. Expand
Cytisine is effective for smoking cessation: should clinicians use it?
  • J. Samet
  • Medicine
  • Evidence-Based Medicine
  • 2014
TLDR
There are diverse approaches to increase the success rate of quit attempts, including approved pharmacological therapies: nicotine-replacement therapy (NRT; available in several forms and over-the-counter), bupropion (an antidepressant) and varenicline (a partial nicotine agonist). Expand
Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: A randomized controlled trial.
TLDR
A randomised controlled trial found that cytisine was at least as effective as varenicline at supporting smoking abstinence in New Zealand indigenous Māori or whānau (extended-family) of Mâori, with significantly fewer adverse events. Expand
Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade.
TLDR
Clinical trials published within the past 10 years investigating novel smoking cessation pharmacotherapies showed promising results, such as cytisine and endocannabinoid modulators, whereas others failed to produce significant effects. Expand
Cytisine for nicotine addiction treatment: A review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.
TLDR
The relative risks of abstinence in the efficacy analysis and RR of ARs, either reported by the authors or calculated from the reports, pooled to provide an updated meta-analysis of cytisine's efficacy and ARs for smoking cessation compared with placebo. Expand
Emerging drugs for the treatment of tobacco dependence: 2014 update
TLDR
Current evidence suggests that the two most effective pharmacotherapies to treat tobacco dependence are varenicline and combination nicotine replacement therapy, both of which demonstrate mixed rates of success in achieving long-term abstinence from smoking. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 14 REFERENCES
Nicotine receptor partial agonists for smoking cessation.
  • K. Lin
  • Medicine
  • American family physician
  • 2011
TLDR
In head-to-head trials, varenicline appears to be at least as effective as nicotine replacement therapy and bupropion and a large cohort study found no increase in the likelihood of depression or suicidality. Expand
Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis
TLDR
Cytisine is an effective treatment for smoking cessation with efficacy comparable to that of other currently licensed treatments, Given its low cost and potential for public health benefit, expedited licensing of cytisine forsmoking cessation is warranted. Expand
Placebo-Controlled Trial of Cytisine for Smoking Cessation
TLDR
This data indicates that smoking and tobacco-related adverse events are more likely to occur in women than in men when the use of non-volatile substance such as tobacco or alcohol is a possibility. Expand
Cytisine and the failure to market and regulate for human health
TLDR
The data are now stronger that cytisine is effective, as two more studies have been added to the meta-analysis and the data had methodological weaknesses that detracted from the evidence. Expand
Nicotine replacement therapy in smoking cessation.
Evidence for benefit from nicotine replacement therapy in hospital patients is inconclusive, although the results of a trial reported in this issue of Thorax give cause for optimism and shouldExpand
Relapse prevention interventions for smoking cessation.
TLDR
There is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid relapse, and most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. Expand
Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis
TLDR
All pharmacologic treatments were significantly more effective than inert controls andVarenicline was the only treatment demonstrating effects over other options, and should be considered in the development of clinical practice guidelines. Expand
Spending on new drug development1.
TLDR
The paper's estimated expenditure on new drug development is somewhat greater than suggested by the survey results presented in DiMasi et al. (J. Health Econ. 2003; 22: 151-185; Drug Inf. 2004; 38: 211-223). Expand
Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine.
TLDR
A novel fused tricyclic analog of cytisine has been prepared and determined to have high affinity at neuronal nicotinic acetylcholine receptors and to have unique cyclopropyl analog possessing a skeleton isoatomic with that of cyt cuisine. Expand
2011 financial report.
  • Marvin Siegel
  • Business, Medicine
  • Journal of infusion nursing : the official publication of the Infusion Nurses Society
  • 2012
TLDR
The financial success enjoyed by INS in 2011 was reported, with an increase of net assets of $178 831 before factoring in unrealized losses on investments, and the total increase in net assets stood at $91 608. Expand
...
1
2
...